196 related articles for article (PubMed ID: 19522503)
1. DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment.
Skladanowski A; Bozko P; Sabisz M
Chem Rev; 2009 Jul; 109(7):2951-73. PubMed ID: 19522503
[No Abstract] [Full Text] [Related]
2. Stopping replication, at the beginning.
Jackson PK
Nat Chem Biol; 2008 Jun; 4(6):331-2. PubMed ID: 18488006
[No Abstract] [Full Text] [Related]
3. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy.
Ashwell S; Zabludoff S
Clin Cancer Res; 2008 Jul; 14(13):4032-7. PubMed ID: 18593978
[TBL] [Abstract][Full Text] [Related]
4. Promises and drawbacks of targeting cell cycle kinases in cancer.
Pentimalli F; Giordano A
Discov Med; 2009 Dec; 8(43):177-80. PubMed ID: 20040266
[TBL] [Abstract][Full Text] [Related]
5. Cdc7 as a potential new target for cancer therapy.
Ito S; Taniyami C; Arai N; Masai H
Drug News Perspect; 2008 Nov; 21(9):481-8. PubMed ID: 19180266
[TBL] [Abstract][Full Text] [Related]
6. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells?
O'Connor PM; Kohn KW
Semin Cancer Biol; 1992 Dec; 3(6):409-16. PubMed ID: 1286161
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of drug inhibition of signalling molecules.
Sebolt-Leopold JS; English JM
Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
[TBL] [Abstract][Full Text] [Related]
8. Targeting the cell cycle: a new approach to cancer therapy.
Schwartz GK; Shah MA
J Clin Oncol; 2005 Dec; 23(36):9408-21. PubMed ID: 16361640
[TBL] [Abstract][Full Text] [Related]
9. Targeted cancer therapies based on the inhibition of DNA strand break repair.
O'Connor MJ; Martin NM; Smith GC
Oncogene; 2007 Dec; 26(56):7816-24. PubMed ID: 18066095
[TBL] [Abstract][Full Text] [Related]
10. DNA damage checkpoints: from initiation to recovery or adaptation.
Bartek J; Lukas J
Curr Opin Cell Biol; 2007 Apr; 19(2):238-45. PubMed ID: 17303408
[TBL] [Abstract][Full Text] [Related]
11. Targeting SMARCAL1 as a novel strategy for cancer therapy.
Zhang L; Fan S; Liu H; Huang C
Biochem Biophys Res Commun; 2012 Oct; 427(2):232-5. PubMed ID: 22995303
[TBL] [Abstract][Full Text] [Related]
12. New checkpoint blockers begin human trials.
Garber K
J Natl Cancer Inst; 2005 Jul; 97(14):1026-8. PubMed ID: 16030295
[No Abstract] [Full Text] [Related]
13. [Molecular mechanism regulating effect of anti-cancer agents].
Saya H
Gan To Kagaku Ryoho; 2009 Jan; 36(1):1-5. PubMed ID: 19151557
[TBL] [Abstract][Full Text] [Related]
14. Targeting the DNA damage response in cancer.
Ljungman M
Chem Rev; 2009 Jul; 109(7):2929-50. PubMed ID: 19545147
[No Abstract] [Full Text] [Related]
15. Chemical strategies for development of ATR inhibitors.
Llona-Minguez S; Höglund A; Jacques SA; Koolmeister T; Helleday T
Expert Rev Mol Med; 2014 May; 16():e10. PubMed ID: 24810715
[TBL] [Abstract][Full Text] [Related]
16. Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy.
Aziz K; Nowsheen S; Pantelias G; Iliakis G; Gorgoulis VG; Georgakilas AG
Pharmacol Ther; 2012 Mar; 133(3):334-50. PubMed ID: 22197993
[TBL] [Abstract][Full Text] [Related]
17. Cell-cycle control in the face of damage--a matter of life or death.
Clarke PR; Allan LA
Trends Cell Biol; 2009 Mar; 19(3):89-98. PubMed ID: 19168356
[TBL] [Abstract][Full Text] [Related]
18. [Target molecules of anti-tumor drugs and cell checkpoints].
Sugimoto K
Rinsho Ketsueki; 2001 May; 42(5):356-8. PubMed ID: 11452450
[No Abstract] [Full Text] [Related]
19. Targeting the DNA damage response for cancer therapy.
Powell SN; Bindra RS
DNA Repair (Amst); 2009 Sep; 8(9):1153-65. PubMed ID: 19501553
[TBL] [Abstract][Full Text] [Related]
20. [Resistance to cytostatic drugs].
Elonen E
Duodecim; 1998; 114(13):1319-28. PubMed ID: 11552258
[No Abstract] [Full Text] [Related]
[Next] [New Search]
